S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war

Allogene Therapeutics Stock Price, News & Analysis (NASDAQ:ALLO)

$2.52
+0.17 (+7.23%)
(As of 12/1/2023 ET)
Compare
Today's Range
$2.23
$2.55
50-Day Range
$2.28
$3.51
52-Week Range
$2.23
$9.60
Volume
2.37 million shs
Average Volume
2.47 million shs
Market Capitalization
$424.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.35

Allogene Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.64 Rating Score
Upside/​Downside
509.0% Upside
$15.35 Price Target
Short Interest
Bearish
30.59% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.10) to ($2.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

383rd out of 957 stocks

Biological Products, Except Diagnostic Industry

62nd out of 161 stocks


ALLO stock logo

About Allogene Therapeutics Stock (NASDAQ:ALLO)

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

ALLO Stock Price History

ALLO Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Earnings Outlook For Allogene Therapeutics
See More Headlines
Receive ALLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/03/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALLO
Fax
N/A
Employees
359
Year Founded
2018

Price Target and Rating

Average Stock Price Target
$15.35
High Stock Price Target
$31.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+509.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
11 Analysts

Profitability

Net Income
$-332,630,000.00
Net Margins
-178,954.28%
Pretax Margin
-178,954.27%

Debt

Sales & Book Value

Annual Sales
$240,000.00
Book Value
$3.47 per share

Miscellaneous

Free Float
122,169,000
Market Cap
$424.07 million
Optionable
Not Optionable
Beta
0.72

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Arie S. Belldegrun F.A.C.S. (Age 74)
    M.D., Co-Founder & Executive Chairman
    Comp: $714.25k
  • Dr. David D. Chang M.D. (Age 63)
    Ph.D., Co-Founder, President, CEO & Director
    Comp: $1.1M
  • Mr. Joshua A. Kazam (Age 46)
    Co-Founder & Director
    Comp: $711k
  • Mr. Geoffrey M. Parker (Age 58)
    Executive VP & CFO
  • Mr. Timothy L. Moore Ph.D. (Age 62)
    Executive VP & Chief Technical Officer
  • Mr. Earl M. Douglas Esq. (Age 60)
    General Counsel & Compliance Officer
  • Ms. Susan R. Lundeen (Age 57)
    Chief People Officer
  • Ms. Christine Cassiano
    Executive VP, Chief Corporate Affairs & Brand Strategy Officer
  • Dr. Zachary J. Roberts M.D. (Age 45)
    Ph.D., Executive VP of Research & Development and Chief Medical Officer
  • Yinlin Chen
    Senior Vice President of Finance














ALLO Stock Analysis - Frequently Asked Questions

Should I buy or sell Allogene Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALLO shares.
View ALLO analyst ratings
or view top-rated stocks.

What is Allogene Therapeutics' stock price target for 2024?

11 Wall Street analysts have issued twelve-month price objectives for Allogene Therapeutics' stock. Their ALLO share price targets range from $6.00 to $31.00. On average, they predict the company's share price to reach $15.35 in the next twelve months. This suggests a possible upside of 509.0% from the stock's current price.
View analysts price targets for ALLO
or view top-rated stocks among Wall Street analysts.

How have ALLO shares performed in 2023?

Allogene Therapeutics' stock was trading at $6.29 at the beginning of the year. Since then, ALLO shares have decreased by 59.9% and is now trading at $2.52.
View the best growth stocks for 2023 here
.

When is Allogene Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our ALLO earnings forecast
.

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) issued its earnings results on Thursday, November, 2nd. The company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.16. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.05 million. Allogene Therapeutics had a negative trailing twelve-month return on equity of 54.03% and a negative net margin of 178,954.28%.

What is David Chang's approval rating as Allogene Therapeutics' CEO?

2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (14.94%), JPMorgan Chase & Co. (4.11%), Primecap Management Co. CA (3.14%), Rafferty Asset Management LLC (0.54%), Barclays PLC (0.47%) and Charles Schwab Investment Management Inc. (0.47%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Owen N Witte, Owen N Witte, Rafael Amado, Stephen Mayo and Veer Bhavnagri.
View institutional ownership trends
.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ALLO) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -